Increased Akkermansia abundance is associated with increased colonic mucosal 00-3 fatty acids and decreased colonic mucosal PGE₂ concentrations following healthy dietary pattern interventions S.B. Rifkin¹, A. Sen², D.K. Turgeon¹, R. Chan^{2,3}, M.T. Ruffin⁴, D.E. Brenner¹, P.D. Schloss⁵, Z. 5 6 Diuric² 1. Michigan Medicine Department of Internal Medicine, Ann Arbor, 48109, USA. 2. Michigan Medicine Department of Family Medicine, Ann Arbor, 48109, USA. 3. Present address:10X Genomics, San Francisco, CA 94111 4. Penn State Cancer Institute, Hershey, PA, 17033, USA. 5. Michigan Medicine Department of Immunology and Microbiology, Ann Arbor, MI, 48109, USA **Corresponding author:** Samara B Rifkin, MD, ScM Division of Gastroenterology and Hepatology University of Michigan School of Medicine srifkin@med.umich.edu Short title: colonic ω-3 fatty acids and Akkermansia **Keywords:** ω -3 polyunsaturated fatty acids (ω -3 PUFA), prostaglandin E₂ (PGE₂), cyclooxygenase (COX) -1 and COX-2, Akkermansia

52 ABSTRACT

- 53 Both increased dietary intake of ω -3 polyunsaturated fatty acids (PUFA) and subsequent increases in
- 54 colonic mucosal ω-3 PUFA concentrations have been linked to improved gut barrier function and
- 55 decreased risks of metabolic diseases and cancer. In addition, increased dietary ω-3 PUFA has been
- 56 linked to eubiosis in mouse studies. Increased ω-3 PUFA function in part to reduce cyclooxygenase-
- 57 (COX) mediated prostaglandin E₂ (PGE₂) production, a biomarker of cancer risk linked to compromised
- 58 gut barrier function. We analyzed data from a dietary intervention study in individuals at increased risk of
- 59 colon cancer to determine whether changes in the mucosal microbiome composition were associated with
- 60 changes in colonic mucosal ω -3/ ω -6-PUFA ratio. Microbiome analyses of colonic biopsies before and
- 61 after the dietary intervention from 86 participants were done by sequencing the V4 region of the 168
- 62 rRNA gene. Multivariable linear regression models were used to evaluate further whether changes in 63 *Akkermansia* was associated with changes in each colonic tissue variable: ω-3/ω-6 PUFA ratios, PGE₂
- concentrations, and expression of COX-1 and COX-2. The median dietary intake and mucosal ω -3/ ω -6
- PUFA ratio increased after intervention. Greater increases in mucosal ω -3/ ω -6 PUFA ratios after
- 66 intervention were significantly associated with several changes in taxon abundance, including increased
- 67 Akkermansia muciniphilia relative abundance. An increased abundance of Akkermansia muciniphilia also
- 68 was associated significantly with decreased PGE₂ concentrations but not with changes in COX
- 69 expression. Further studies are warranted to elucidate mechanisms by which Akkermansia may affect or is

70 affected by these pathways and the relative importance of individual dietary components.

103 Introduction

104

105 Chronic low grade inflammation has been implicated in the rising prevalence of chronic diseases

- 106 including obesity, diabetes, cardiovascular diseases and cancer.^{1,2} It has been suggested that Western
- 107 diets containing relatively high saturated fatty acids and ω -6 polyunsaturated fatty acids (PUFA) but low
- 108 monounsaturated fatty acids (MUFA) and ω-3 PUFA contribute to pro-inflammatory states and the rising
- 109 prevalence of chronic diseases.³ In particular, consumption of ω -3 PUFA from fish and other foods
- 110 results in a more favorable eicosanoid profile to reverse the chronic inflammation associated with reduced
- 111 risks of obesity, diabetes and cancer.^{4–6} Dietary fats, however, have multi-faceted effects on inflammation
- 112 and chronic diseases that also appears to include changes in the microbiome and gut barrier function.²
- 113

114 High saturated fat diets have been shown to compromise gut barrier function through mucus thinning and

115 loss of junction barrier proteins leading to metabolic endotoxemia.^{2,7,8} Systemic exposures to bacterial

116 lipopolysaccharides (LPS) are thought to mediate this process. LPS, a major component of the gram

117 negative bacterial outer membrane, can be absorbed into the bloodstream to stimulate toll like receptor 4

118 (TLR4) with reactive elevations in serum pro-inflammatory eicosanoids and cytokines.^{2,8,9} Conversely,

119 certain anti-inflammatory dietary components, including ω-3 PUFA, have been shown to prevent or

120 reverse metabolic endotoxemia and chronic low grade inflammation by improving gut barrier

- 121 function.^{2,8,10}
- 122

123 Dietary ω-3 PUFA affect gut barrier function by several mechanisms. The ω-3 PUFA inhibit formation of pro-inflammatory eicosanoids such as prostaglandin E₂ (PGE₂) from the cyclooxygenase (COX-1) and 124 125 COX-2-mediated oxidation of arachidonic acid (AA), and the reduction in PGE₂ signaling reduces local inflammatory reactions to maintain normal barrier function.¹¹ The ω-3 PUFA compete with AA as 126 127 substrates for COX-1 and COX-2 enzymes and eicosapentaenoic acid ω-3 (EPA) also binds to COX-1 to allosterically inhibit AA oxygenation.¹² In addition, ω -3 PUFA may prevent inflammation by 128 influencing microbiome composition.¹³ A preponderance of studies have found that ω -3 PUFA 129 administration increases LPS-suppressing bacteria including Akkermansia mucinophila.^{2,10,14–19} Increased 130 131 tissue ω -3 PUFA in a transgenic mouse model that endogenously produces ω -3 PUFA led to lower levels 132 of LPS-producing bacteria and higher levels of LPS-suppressing bacteria versus that in wild type mice.^{10,14} In human studies, the presence of *A. mucinophila* in the outer mucus layer of the colon was 133 134 associated with reduction of metabolic endotoxemia and chronic low-grade inflammation brought on by 135 high fat diet and obesity. These beneficial effects were attributed to the role of A. mucinophila in maintaining gut barrier function.¹⁶ 136 137

138 Most studies aimed at investigating the relationship between PUFAs and intestinal microbiome 139 composition have quantified the intestinal microbiota in excreted stool and measured PUFAs in the 140 serum. Excreted stool, however, does not reflect the bacterial milieu adhering to the colonic mucosal 141 surface.²⁰ Bacteria adhering to the colonic mucin are in close proximity to the colon epithelial cells. 142 Therefore, characterizing the bacteria associated with the colonic mucosa may be more meaningful to 143 evaluate in the interaction between the diet and the gut microbiome. In the present study, we performed a 144 secondary analysis of a study that recruited individuals with an elevated risk of colorectal cancer and 145 randomized them to either a Healthy Eating diet or a Mediterranean diet. Both diet arms achieved similar 146 increases in median dietary and median colonic mucosal ω -3/ ω -6 PUFA ratios, but there was substantial 147 inter-individual variability in fatty acid changes within each arm. This afforded the opportunity to 148 evaluate whether changes in the colonic mucosal microbiome were associated with changes in colonic 149 mucosal ω -3/ ω -6 PUFA ratios. Because of its known role in promoting colonic integrity and limiting 150 metabolic endotoxemia, we investigated further whether Akkermansia abundance was associated with 151 colonic mucosal ω -3/ ω -6 PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression and PGE₂ 152 using multivariable linear regression models.

- 153
- 154 <u>Methods</u>
- 155

156 <u>The Healthy Eating Study</u>

Methods for conducting the Healthy Eating Study have been previously published.²¹ This study was 157 158 conducted according to the Declaration of Helsinki and all procedures involving human subjects were 159 approved by The University of Michigan Institutional Review Board (HUM00007622). This study was 160 registered at ClinicalTrials.gov (registration no. NCT00475722). In brief, 120 persons at increased risk of 161 colorectal cancer were enrolled from Ann Arbor, MI, and surrounding areas from July 2007 to November 162 2010. Increased risk was defined as having a family history of colorectal cancer in either one first-degree 163 relative or two second-degree relatives, or having a personal history of colorectal adenoma or cancer. All 164 study participants provided informed, signed consent prior to randomization.

- 165
- 166 A total of 94 participants completed 6 months of study. Participants underwent un-prepped flexible
- 167 sigmoidoscopy before and after the 6-month intervention. Eight colorectal biopsy samples were obtained
- 168 from the colon, 20 to 25 cm from the anal sphincter. Biopsy samples were flash frozen in liquid nitrogen
- 169 within 5 seconds and kept at -70°C until analysis. Colon biopsy samples were available
- 170 for microbiome analysis from 94 participants at baseline and from 86 participants after dietary

171 intervention. Blood was collected after an overnight fast and prepared serum was kept frozen at -80 °C

- 172 until analysis.
- 173

174 Measures of fatty acids, prostaglandin E₂, COX-1 and COX-2

175 Serum and colon biopsy samples were analyzed for complete fatty acid profiles as methyl esters using gas

176 chromatography—mass spectroscopy (GC-MS). ω-3 PUFA was calculated by summing 18:3, 20:5, and

177 22:6, whereas ω -6 PUFA was calculated by summing 18:2 (n6), 20:3 (n6), 20:4 (n6). The ratio was then

178 produced dividing ω -3 PUFA by ω -6 PUFA. PGE₂ in colon mucosal biopsy samples was analyzed using

179 liquid chromatography with mass spectrometry as previously described.¹² COX-1 and COX-2 gene

- 180 expression was quantified by Quantitative real-time PCR.²²
- 181

182 <u>Dietary intervention</u>

183 Participants were randomized to receive dietary counseling to follow either a Healthy Eating diet or a

184 Mediterranean diet and the specific details of the two dietary interventions have been published

previously.²¹ Overall, the change in dietary ω -3/ ω -6 PUFA ratios and colonic mucosal ω -3/ ω -6 PUFA

186 ratios were similar between the two study arms, however there was inter-individual variation in fatty acid

187 intakes and colonic tissue levels across the entire study population that allowed us to perform this

- 188 secondary data analysis.²¹
- 189

190 Dietary data was obtained at baseline and 6 months using two 24-hour recalls and two days of written

191 food records (four non-consecutive days per time point). The analysis of food records and recalls were

192 performed with the Nutrition Data System for Research (2013 version; University of Minnesota, Nutrition

193 Coordinating Center). Food and nutrient intakes were averaged over the four days of intake for each

194 subject at each time point.

195

196 <u>Mucosal microbiome 16S rRNA sequencing and processing</u>

DNA was isolated from biopsy samples using PowerMag Microbiome RNA/DNA Isolation Kit (Mo Bio
 Laboratories, Inc) and epMotion 5075 liquid handling system (Eppendorf). The hypervariable V4 region

199 was amplified using primers described previously and 16S rRNA gene sequences were processed using

200 the mothur software package.²³ FASTQ files were generated for paired end reads. Paired-end reads were

201 merged into contigs, aligned to the SILVA 16S rRNA sequence database (version 138), and low quality

202 sequences and chimeras were removed.²⁴ Sequences were classified by training a naive Bayesian

203 classifier with a 16S rRNA gene training set (Ribosomal Database Project (RDP)).²⁵ Sequences were then

204 clustered into operational taxonomic units (OTUs) using a 97 % similarity cutoff with the OptiClust

clustering algorithm.²⁶ Samples were rarefied to 1,047 sequences per sample, which eliminated ten of 179
 samples.

- 207
- 208 <u>Statistical analysis</u>

209 Individuals were categorized according to baseline colonic mucosal ω -3/ ω -6 PUFA ratios tertiles. 210 Baseline characteristics variables were tested for normality using the Shapiro-Wilk's method in R 211 (version 4.0.2), which did not follow a normal distribution. Therefore, these values were assessed using 212 medians and interquartile ranges for continuous variables, and as frequencies and percentages for 213 categorical variables. Additionally, fatty acid dietary intake, serum and colonic mucosal concentrations 214 before and after dietary intervention did not follow a normal distribution. We therefore calculated median 215 differences in these variables before and after intervention. Statistically significant changes in median 216 differences in nutrient variables were assessed using Wilcoxon signed rank test.

217

218 We characterized variation in microbial community using metrics for 1) α diversity (Shannon index) to 219 quantify intraindividual variation and 2) β -diversity-based distance metric (Bray-Curtis) to quantify the 220 distance between individuals. These values were calculated using mothur software package. We 221 compared Shannon index across serum, diet and colonic mucosal ω -3/ ω -6 PUFA ratios tertiles using 222 Kruskal-Wallis. Associations between microbiome variation and serum, diet and colonic mucosal ω -3/ ω -223 6 PUFA ratios were assessed via permutational multivariate analysis of variance (PERMANOVA) both as 224 continuous variables and using variables categorized into tertiles. To visualize the Bray-Curtis distance 225 values between samples, Non-metric multidimensional scaling-NMDS was calculated and results were 226 plotted using the vegan package within the R program. 227

Linear regression was used to identify bacterial taxa whose relative abundance were associated with changes in of serum, diet and colonic mucosal ω -3/ ω -6 PUFA ratios. The Benjamini-Hochberg (B-H) method was used to adjust P values in the multiple correlation analyses while controlling for the expected false discovery rate at 0.05. We then constructed a multivariable linear regression models for each colonic mucosal variable (ω -3/ ω -6 PUFA ratio, PGE₂ levels, COX-1 and COX-2 gene expression) to assess if a

- 233 given colonic mucosal variable was associated with *Akkermansia* abundance. We modeled each colonic
- mucosal variable (ω -3/ ω -6 PUFA ratio, PGE₂ levels, COX-1 and COX-2 gene expression) at 6 months as
- a factor of log change in *Akkermansia* abundance levels after intervention, also adjusting for the colonic

236 mucosal variable at baseline and age, sex and body mass index (BMI).

237

238 <u>Results</u>

239 Baseline characteristics of study participants

240 The 86 study participants with sequenced biopsy samples available at one or both time points were 74%

- female, had a median age of 54 years, and a median BMI of 27 kg/m². A small proportion of participants
- 242 (18%) were taking nonsteroidal anti-inflammatory drugs (NSAIDs). Baseline data are shown by tertiles of
- 243 colonic mucosal ω -3/ ω -6 PUFA ratios (Table 1). Age, BMI, sex, NSAID use, and PGE₂ were not
- 244 different across tertiles of colonic mucosal ω -3/ ω -6 PUFA ratios.
- 245
- 246 Effects of dietary intervention on fatty acid intake and concentrations
- 247 Median differences in fatty acid intake, serum and colonic mucosal concentrations after each dietary
- 248 intervention are shown in Table 2. Dietary ω-3 PUFA increased in the Healthy Eating arm (P=0.04),
- 249 while dietary ω -6 PUFA decreased in the Mediterranean arm (P<0.0001). The dietary ω -3/ ω -6 PUFA
- 250 ratio increased in both the Healthy Eating arm (P=0.01) and the Mediterranean arm (P=0.0002). Serum ω -
- 251 3 PUFA increased in the Healthy Eating arm (P=0.004) and serum ω -6 PUFA decreased in the
- 252 Mediterranean arm (P=0.04). The median serum ω -3/ ω -6 PUFA ratio remained the same in the Healthy
- Eating arm and increased from 0.09 to 0.12 in the Mediterranean arm (P=0.03). Median colonic mucosal
- 254 PGE₂ concentrations did not change appreciably in the Healthy Eating arm (P=0.8) nor the Mediterranean
- arm after 6 months of intervention (P=0.7). The colonic mucosal ω -3/ ω -6 PUFA ratio increased in both
- the Healthy Eating arm (P=0.03) and the Mediterranean arm (P=0.001). We confirmed that both arms
- 257 achieved similar changes in colonic mucosal ω -3/ ω -6 PUFA ratio. However, there was substantial inter-
- 258 individual variation in colonic mucosal concentrations of all these analytes.
- 259

260 Effects of fatty acid concentrations on gut microbiota

- 261 To test the hypothesis that fatty acids can influence the microbiome, we examined how global
- 262 microbiome features, including within community variation (alpha diversity with Shannon index) and
- 263 between community variation (beta diversity using Bray-Curtis distance), varied according to colonic
- 264 mucosal, serum and dietary fatty acid levels.²² The Shannon index was inversely associated with baseline
- 265 colonic mucosal ω -3/ ω -6 PUFA (P=0.02), but not associated with serum ω -3/ ω -6 PUFA ratio at baseline
- 266 nor any of these variables at 6 months after intervention (Figure 1).
- 267
- 268 When we performed PERMANOVA analysis, we found no differences in beta diversity or community
- distance according to diet (P= 0.5), or colonic mucosal ω -3/ ω -6 PUFA ratio at 6 months (P= 0.1),
- 270 however serum ω -3/ ω -6 PUFA ratio at 6 months showed a stronger association with beta diversity
- 271 (P=0.003). We also performed PERMANOVA analysis using dietary (P=1.00), serum (P=0.09) and
- 272 colonic mucosal ω -3/ ω -6 PUFA ratio (P= 0.46) categorized into tertiles and found no differences in beta

273	diversity (see Figure 2). We found that when we performed pairwise PERMANOVA on serum ω -3/ ω -6
274	PUFA ratio levels tertiles at 6 months that none of the differences were significant (P=0.5).
275	
276	Abundance of taxa by colonic mucosal, serum and dietary ω -3/ ω -6 PUFA ratios at baseline
277	We identified several differentially abundant genera that were positively associated with baseline colonic
278	mucosal ω-3/ω-6 PUFA ratio including Varibaculum, Rhizobium, Porphyrmonas, Mogibacterium,
279	Megamonas, Coprobacillus, Butyrcicoccus, Actinomyces and unclassified members of
280	<i>Erysipelotrichaceae</i> . Unclassifed members of <i>Lachnospiracea</i> were negatively associated with ω -3/ ω -6
281	PUFA ratio (Figure 3).
282	
283	The following genera were positively associated with baseline serum ω -3/ ω -6 PUFA ratio (Figure 3):
284	Rothia, Phyllobacterium, Negativicoccus, Leuconostoc, Hydrogenoanaerobacterium, Enterococcus,
285	Clostridium sensu stricto, Cloacibacterium, Brochothrix and unclassified members of Proteobacteria and
286	Actinobacteria. Rothia, Phyllobacterium, Enterococcus, Coprobacilus, Butyrcicoccus, Brochothrix,
287	Anaeotruncus and unclassified member of Actinobacteria were positively associated with dietary ω -3/ ω -6
288	PUFA ratio levels.
289	
290	Abundance of taxa by colonic mucosal, serum and dietary ω -3/ ω -6 PUFA ratios after 6 months
291	We identified several differentially abundant genera whose relative abundance were positively associated
292	with colonic mucosal ω -3/ ω -6 PUFA ratio including unclassified members of <i>Alphaproteobacteria</i> ,
293	Clostridia and Lachnospiracea, and Akkermansia at 6 months. Odoribacter was negatively associated
294	with colonic mucosal ω -3/ ω -6 PUFA ratio at 6 months (Figure 3).
295	
296	The following genera were positively associated with serum ω -3/ ω -6 PUFA ratio (Figure 3):
297	Varibaculum, Acinetobacter, Arcanobacterium, Stentotrophomonas, Streptococcus, Actinobaculum,
298	Actinomyces, Subdoligranulum, and unclassified members of Betaproteobacteria, while Blautia, Dorea
299	and Bifidobacterium were negatively associated at 6 months. Veillonella, Streptococcus, Butyricicoccus,
300	<i>Helococcus</i> and unclassified members of <i>Clostridiales</i> were positively associated with dietary ω -3/ ω -6
301	PUFA ratio levels.
302	
303	<u>Akkermansia</u> abundance and colonic mucosal ω -3/ ω -6 PUFA ratio, COX gene expression, PGE ₂
304	concentration
305	We further investigated whether Akkermansia abundance was associated with colonic mucosal ω -3/ ω -6
306	PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression, PGE ₂ levels adjusting for age,

307 BMI, sex and dietary ω -3/ ω -6 PUFA ratio intake. COX-1 and COX-2 were not associated with ω -3/ ω -6 308 PUFA ratio. We investigated whether these colonic mucosal nutrient concentrations, gene expression and 309 metabolite concentrations were associated with levels of *Akkermansia* abundance using two different 310 linear models.

311

312 To assess the effect of change in *Akkermansia* abundance on colonic mucosal ω -3/ ω -6 PUFA ratio, PGE₂, 313 COX-1 and COX-2 gene expression following the dietary intervention, we modeled each colonic mucosal 314 variable at 6 months as the dependent variable adjusting for each colonic mucosal variable at baseline and 315 change in Akkermansia abundance using linear regression (Table 3). We found that a positive log change 316 in Akkermansia following the dietary intervention was significantly associated with increased colonic 317 mucosal ω -3/ ω -6 PUFA ratios at 6 months after adjusting for age, sex, BMI, and dietary ω -3/ ω -6 PUFA 318 ratios (P=0.02). When we modeled colonic mucosal PGE₂ at 6 months with adjustment for baseline 319 values, a negative log change in Akkermansia following the intervention conversely was associated with a 320 positive change in colonic mucosal PGE₂ (P=0.01). COX-1 or COX-2 expression at 6 months were not

- 321 associated with log change in *Akkermansia* abundance (P=0.3) and (P=0.5), respectively.
- 322

323 Discussion

324 The two dietary intervention arms resulted in similar changes in serum and colonic mucosal ω -3/ ω -6 325 PUFA ratios (Table 2). We therefore analyzed changes in colonic mucosal measures and in bacterial 326 populations in all 86 study participants combined. The colonic mucosal ω -3/ ω -6 PUFA ratio increased in 327 the combined study population. Overall, we found that differences in PUFA incorporated in colonic 328 tissues were not associated with global changes in the microbiome, but they were associated with specific 329 microbiome changes. Alpha diversity, i.e. within community diversity, was associated with colonic 330 mucosal ω -3/ ω -6 PUFA ratios at baseline, but otherwise not associated with dietary or serum ω -3/ ω -6 331 PUFA ratio at baseline or any nutrient ratios at 6 months (Figure 1). Beta diversity, i.e. inter-sample 332 diversity, varied according to serum but not colonic mucosal ω -3/ ω -6 PUFA concentration at 6 months 333 (Figure 2). Our results analyzing differential taxon abundance associated with changes in ω -3/ ω -6 PUFA 334 ratio are consistent with both mouse studies and clinical interventions, which also found that higher ω -3 PUFA levels may influence the abundance of short chain fatty acid (SCFA) producing bacteria.^{10,15,17-} 335 ^{19,27,28} Several studies involving ω-3 supplementation reported increases in SCFA-producing 336 bacteria.^{15,17,19,29,30} We also found a positive association between *Lachnospiracea* and colonic mucosal ω-337 338 3/00-6 PUFA ratios, but an inverse association with *Odoribacter*, both producers of SCFA (Figure 3). 339

340 In subsequent analyses, we focused on the association between Akkermansia abundance and colonic 341 mucosal ω -3/ ω -6 PUFA ratio concentrations that had emerged in taxon-wide analyses since a lot of information is available on the role of Akkermansia muciniphilia in colon health.^{1,8,16} In addition to 342 343 colonic mucosal PUFA, we explored the association between Akkermansia abundance and PGE₂ a pro-344 inflammatory mediator in the colon.³¹ PGE_2 is produced from COX-mediated oxygenation of arachidonic 345 acid, an ω -6 PUFA. We found that increased abundance of the A. muciniphilia after 6 months of dietary 346 intervention was significantly and independently associated with increased colonic mucosal ω -3/ ω -6 347 PUFA ratios and with decreased PGE₂ concentrations using two different types of linear models, 348 adjusting for age, sex and BMI. This did not appear to be due to changes in COX-1 or COX-2 expression 349 in colonic biopsy tissues. 350 351 *A. muciniphilia* is found within the mucin layer and therefore is likely to impact the gut barrier function. 352 Higher levels of Akkermansia abundance have been linked to decreased serum LPS levels, improved 353 insulin resistance and low grade chronic inflammation.¹⁶ While obesity and high fat diets were associated 354 with decreased levels of Akkermansia abundance, Akkermansia supplementation improved metabolic 355 endotoxemia, hyperglycemia, and adiposity in mice fed a high fat diet.¹⁶ Additionally, Akkermansia is 356 enriched in people who consume other diets that are known to enhance barrier function and improve 357 metabolic endotoxemia, including general anti-inflammatory dietary patterns and functional foods rich in polyphenols including extracts of black raspberry, concord grape and cranberry.^{2,32–36} 358 359 360 Our findings of increased Akkermansia levels with higher colonic tissue ω -3/ ω -6 PUFA ratios are compatible with prior animal studies and clinical interventions.^{9,14,17,18} Several murine models have also 361 362 demonstrated that fish oil supplementation resulting in increased colonic mucosal ω -3/ ω -6 ratios led to higher Akkermansia abundance levels, among other taxon.^{9,14,18} The association between Akkermansia and 363 364 two variables in the same pathway in the expected directions makes a stronger argument for a causal 365 relationship, however we did not find an association between increased ω -3/ ω -6 PUFA ratios and 366 decreased PGE₂ concentrations following the dietary intervention. Furthermore, the association between 367 PGE₂ and Akkermansia abundance was not weakened when ω -3/ ω -6 PUFA ratio was included in the 368 model. 369 370 While there is accumulating evidence that colonic ω -3 PUFA may modify the colonic mileau and 371 encourage the growth of Akkermansia, it is unclear how Akkermansia abundance may be influencing

372 colonic mucosal PGE2 levels or vice versa. A relevant mouse study demonstrated that increased SCFA

373 levels promoted an increased PGE₁/PGE₂ ratio that in turn stimulated myofibroblast to express MUC-2,

an important component of barrier integrity.³⁷ Conversely, another mouse study found that increased 374 375 PGE₂ through its receptor EP4 reduced SCFA-producing bacteria leading to repression of intestinal Treg accumulation and accumulation of intestinal inflammation.³⁸ While we speculate that colonic mucosal 376 377 PUFA may influence the mucosal adherent microbiome, but the reverse or both directions could be true. 378 Furthermore, we hypothesize that Akkermansia abundance may lead to improved gut barrier function and 379 limit PGE_2 production, but the reverse could be true. Therefore, the direction of the proposed effect 380 cannot be determined from a statistical model and should also be interpreted with caution. 381 382 Both increased ω -3 PUFA and A. muciniphilia may alleviate the pathogenesis of obesity and high 383 saturated fat diet on chronic low grade inflammation by limiting metabolic endotoxemia and strengthening gut barrier function.^{16,39} In transgenic fat-1 mice that endogenously convert ω -6 PUFA to 384 385 ω -3 PUFA, transgenic fat-1 mice harbored lower levels of LPS producing bacteria and higher levels of LPS-suppressing bacteria (*Bifidobacterium*, A. *muciniphilia*) as compared with wild type mice.¹⁴ These 386 387 mice also demonstrated increased expression of intestinal alkaline phosphatase (IAP), an anti-388 inflammatory enzyme located on the brush border that protects against pathogenic bacteria. Notably IAP 389 promotes anti-inflammatory effects on the GI mucosa by dephosphorylating microbial LPS and 390 microbiota-produced ATP, an important inflammatory mediator.¹⁴ IAP has also been linked to improved gut barrier function and has been shown to alleviate metabolic disease.^{14,40} The authors hypothesized that 391 392 increased tissue ratio of ω -3/ ω -6 PUFA ratios led to increased expression of IAP which cultivated an intestinal milieu favoring growth of LPS-suppressing bacteria.¹⁴ 393 394 395 One strength of this study is the availability of colonic tissue for the fatty acid measures. Few studies 396 have assessed the effect of colonic mucosal ω -3 PUFA on microbiome, and most studies have relied on 397 self-reported diet, serum or RBC concentrations of ω -3 PUFA. Fatty acids are absorbed efficiently by the 398 proximal small intestine with little residual traveling to the colon to affect the luminal microbiome 399 composition.⁴¹ Therefore, the PUFA composition of colonic tissue more likely influences microbiome 400 composition via indirect effects on the nature of the colonic barrier. The beneficial effects of colonic 401 mucosal ω -3 PUFA have been shown to be manifested in part due to improved gut barrier function in both animal models and human intervention studies.^{39,42} In addition, our study also sequenced the 402 403 microbiome adhering to colonic mucosal biopsies. Colonic mucosal fatty acids are more likely to affect

404 bacteria associated with the mucosa, such as *A. muciniphilia*, a bacterium known to reside in the mucin in

405 close proximity to the mucosa.

407 There are also several limitations to this study that should be recognized. The data in this study was

408 analyzed using 16S rRNA and therefore our ability to determine changes in microbial function is limited.

409 In addition, 16S rRNA analysis only allows resolution to the genus level. However, A. muciniphilia is the

- 410 only bacterium of its genus known to colonize humans and therefore misclassification for this finding is
- 411 unlikely. Lastly, sample size limited our ability to adjust for multiple covariates simultaneously.
- 412
- 413 In summary, we report a positive association between mucosal Akkermansia abundance and colonic tissue
- 414 ω -3/ ω -6 PUFA ratios and a negative association with colonic PGE₂ concentrations in subjects who had
- 415 undergone dietary intervention, either Mediterranean or Healthy Eating, both of which resulted in similar
- 416 dietary changes with the exception of monounsaturated fats. These results are consistent with animal
- 417 models and human studies that provide accumulating evidence of a connection between ω -3 PUFA and
- 418 increased *Akkermansia* abundance on gut barrier function. Our growing understanding of how both ω-3
- 419 PUFA and *Akkermansia* improve gut barrier function and potentially limit metabolic endotoxemia is
- 420 compelling as a causal association between diet, microbiome and chronic low-grade inflammation. Future
- 421 studies exploring the effect of colonic mucosal ω -3/ ω -6 PUFA ratios on the microbiome, on A.

422 *muciniphilia* in particular, and gut barrier function are warranted.

423

424

425 426

428 Acknowledgements

429

430 We thank all the individuals who volunteered to participate in the Healthy Eating Study. We acknowledge

the contributions of Maria Cornellier in conducting the dietary counseling, Mary Rapai for study

432 recruitment and coordination, Dr. Elkhansa Sidahmed for carrying out the gene expression analyses, Faith

433 Umoh for carrying out the assays for LBP, and Jianwei Ren for the analyses of fatty acids, carotenoids

- and eicosanoids.
- 435

436 Financial Support

437

438 We acknowledge support from the University of Michigan Medical School Host Microbiome Initiative

and NIH grants RO1 CA120381, Cancer Center Support Grant P30 CA046592, and the Rose and

440 Lawrence C. Page, Sr. Family Charitable Foundation (to Dr. D. Kim Turgeon). Rena Chan was supported

441 by the Cancer Biology Training Program grant T32 CA009676. The research used core resources

442 supported by a Clinical Translational Science Award, NIH grant UL1RR024986 (the Michigan Clinical

443 Research Unit), by the Michigan Diabetes Research Center, NIH grant 5P60 DK20572 (Chemistry

Laboratory), the Michigan Nutrition and Obesity Research Center, and NIH grant P30 DK089503.

445 Conflict of Interest

446 The authors have no financial, professional or personal conflicts of interest to disclose.

447 **Authors' contributions:**

448 SR wrote the paper, analyzed data had primary responsibility for the final content. AS designed the

449 research and analyzed data. RC performed data management and statistical analysis. MTR, DB and DKT

450 designed the research. PDS analyzed data and wrote the paper. ZD designed the research, obtained the 451 funding, and wrote the paper.

- 452
- 517
- 518

519

522

523

524

525 526

520

528

529 530

531

532 533

534

535

536

539	
540	References
541	
542	1. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic
543	disease. Curr Pharm Des. 2009;15(13):1546-1558. doi:10.2174/138161209788168164
544	2. Bidu C, Escoula Q, Bellenger S, et al. The Transplantation of ω3 PUFA-Altered Gut Microbiota
545	of fat-1 Mice to Wild-Type Littermates Prevents Obesity and Associated Metabolic Disorders. <i>Diabetes</i> .
546	2018;67(8):1512-1523. doi:10.2337/db17-1488
547	3. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation:
548	nutritional implications for chronic diseases. <i>Biomed Pharmacother</i> . 2006;60(9):502-507.
549	doi:10.1016/j.biopha.2006.07.080
550	4. Bender N, Portmann M, Heg Z, Hofmann K, Zwahlen M, Egger M. Fish or n3-PUFA intake and
551	body composition: a systematic review and meta-analysis. <i>Obes Rev Off J Int Assoc Study Obes</i> .
552	2014;15(8):657-665. doi:10.1111/obr.12189
553	5. Abbott KA, Burrows TL, Acharya S, Thota RN, Garg ML. DHA-enriched fish oil reduces insulin
554	resistance in overweight and obese adults. <i>Prostaglandins Leukot Essent Fatty Acids</i> . 2020;159:102154.
555	doi:10.1016/j.plefa.2020.102154
556 557	6. Wang J, Zhang Y, Zhao L. Omega-3 PUFA intake and the risk of digestive system cancers: A
558	meta-analysis of observational studies. <i>Medicine (Baltimore)</i> . 2020;99(19):e20119. doi:10.1097/MD.00000000020119
559	7. Mani V, Hollis JH, Gabler NK. Dietary oil composition differentially modulates intestinal
560	endotoxin transport and postprandial endotoxemia. <i>Nutr Metab.</i> 2013;10(1):6. doi:10.1186/1743-7075-
561	10-6
562	8. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin
563	resistance. <i>Diabetes</i> . 2007;56(7):1761-1772. doi:10.2337/db06-1491
564	9. Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk between Gut
565	Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling. <i>Cell Metab</i> .
566	2015;22(4):658-668. doi:10.1016/j.cmet.2015.07.026
567	10. Monk JM, Liddle DM, Hutchinson AL, et al. Fish oil supplementation to a high-fat diet improves
568	both intestinal health and the systemic obese phenotype. <i>J Nutr Biochem.</i> 2019;72:108216.
569	doi:10.1016/j.jnutbio.2019.07.007
570	11. Durkin LA, Childs CE, Calder PC. Omega-3 Polyunsaturated Fatty Acids and the Intestinal
571	Epithelium-A Review. Foods Basel Switz. 2021;10(1). doi:10.3390/foods10010199
572	12. Wilson MJ, Sen A, Bridges D, et al. Higher baseline expression of the PTGS2 gene and greater
573	decreases in total colonic fatty acid content predict greater decreases in colonic prostaglandin-E2
574	concentrations after dietary supplementation with ω-3 fatty acids. <i>Prostaglandins Leukot Essent Fatty</i>
575	Acids. 2018;139:14-19. doi:10.1016/j.plefa.2018.11.001
576	13. Bellenger J, Bellenger S, Escoula Q, Bidu C, Narce M. N-3 polyunsaturated fatty acids: An
577	innovative strategy against obesity and related metabolic disorders, intestinal alteration and gut
578	microbiota dysbiosis. Biochimie. 2019;159:66-71. doi:10.1016/j.biochi.2019.01.017
579	14. Kaliannan K, Wang B, Li X-Y, Kim K-J, Kang JX. A host-microbiome interaction mediates the
580	opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci Rep. 2015;5:11276.
581	doi:10.1038/srep11276
582	15. Pu S, Khazanehei H, Jones PJ, Khafipour E. Interactions between Obesity Status and Dietary
583	Intake of Monounsaturated and Polyunsaturated Oils on Human Gut Microbiome Profiles in the Canola
584	Oil Multicenter Intervention Trial (COMIT). Front Microbiol. 2016;7. doi:10.3389/fmicb.2016.01612
585	16. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal
586	epithelium controls diet-induced obesity. <i>Proc Natl Acad Sci U S A</i> . 2013;110(22):9066-9071.
587	doi:10.1073/pnas.1219451110

- 588 17. Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3 polyunsaturated
- fatty acid supplements on the human intestinal microbiota. *Gut.* 2018;67(11):1974-1983.
- 590 doi:10.1136/gutjnl-2017-314968
- 591 18. Ghosh S, DeCoffe D, Brown K, et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-
- induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. *PloS One.* 2013;8(2):e55468. doi:10.1371/journal.pone.0055468
- Menni C, Zierer J, Pallister T, et al. Omega-3 fatty acids correlate with gut microbiome diversity
 and production of N-carbamylglutamate in middle aged and elderly women. *Sci Rep.* 2017;7(1):11079.
 doi:10.1038/s41598-017-10382-2
- 597 20. Flynn KJ, Ruffin MT, Turgeon DK, Schloss PD. Spatial Variation of the Native Colon
- 598 Microbiota in Healthy Adults. *Cancer Prev Res Phila Pa*. 2018;11(7):393-402. doi:10.1158/1940-599 6207.CAPR-17-0370
- 600 21. Sidahmed E, Cornellier ML, Ren J, et al. Development of exchange lists for Mediterranean and 601 Healthy Eating diets: implementation in an intervention trial. *J Hum Nutr Diet Off J Br Diet Assoc*.
- 602 2014:27(5):413-425. doi:10.1111/jhn.12158
- 603 22. Djuric Z, Bassis CM, Plegue MA, et al. Colonic Mucosal Bacteria Are Associated with Inter-
- Individual Variability in Serum Carotenoid Concentrations. *J Acad Nutr Diet*. 2018;118(4):606-616.e3.
 doi:10.1016/j.jand.2017.09.013
- 606 23. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a Dual-Index
- 607 Sequencing Strategy and Curation Pipeline for Analyzing Amplicon Sequence Data on the MiSeq
 608 Illumina Sequencing Platform. *Appl Environ Microbiol*. 2013;79(17):5112-5120.
- 609 doi:10.1128/AEM.01043-13
- 610 24. Pruesse E, Quast C, Knittel K, et al. SILVA: a comprehensive online resource for quality checked 611 and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res.* 2007;35(21):7188-
- 612 7196. doi:10.1093/nar/gkm864
- 613 25. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of
- rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol*. 2007;73(16):5261-5267.
 doi:10.1128/AEM.00062-07
- 616 26. Westcott SL, Schloss PD. OptiClust, an Improved Method for Assigning Amplicon-Based
 617 Sequence Data to Operational Taxonomic Units. *mSphere*. 2017;2(2). doi:10.1128/mSphereDirect.00073618 17
- 619 27. Noriega BS, Sanchez-Gonzalez MA, Salyakina D, Coffman J. Understanding the Impact of
- 620 Omega-3 Rich Diet on the Gut Microbiota. *Case Rep Med.* 2016;2016:3089303.
- 621 doi:10.1155/2016/3089303
- 622 28. Calder PC. Is Increasing Microbiota Diversity a Novel Anti-Inflammatory Action of Marine n-3
 623 Fatty Acids? *J Nutr.* 2019;149(7):1102-1104. doi:10.1093/jn/nxz043
- 624 29. Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut
 625 Microbiota. *Int J Mol Sci.* 2017;18(12). doi:10.3390/ijms18122645
- 626 30. Balfegó M, Canivell S, Hanzu FA, et al. Effects of sardine-enriched diet on metabolic control,
- 627 inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.
- 628 Lipids Health Dis. 2016;15:78. doi:10.1186/s12944-016-0245-0
- 629 31. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer:
- 630 the role of prostaglandin E2. *Oncology*. 2005;69 Suppl 1:28-32. doi:10.1159/000086629
- 631 32. Zheng J, Hoffman KL, Chen J-S, et al. Dietary inflammatory potential in relation to the gut
- microbiome: results from a cross-sectional study. *Br J Nutr*. Published online June 1, 2020:1-12.
 doi:10.1017/S0007114520001853
- 634 33. Tu P, Bian X, Chi L, et al. Characterization of the Functional Changes in Mouse Gut Microbiome
- 635 Associated with Increased Akkermansia muciniphila Population Modulated by Dietary Black
- 636 Raspberries. ACS Omega. 2018;3(9):10927-10937. doi:10.1021/acsomega.8b00064

637 Roopchand DE, Carmody RN, Kuhn P, et al. Dietary Polyphenols Promote Growth of the Gut 34.

638 Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome.

639 Diabetes. 2015;64(8):2847-2858. doi:10.2337/db14-1916

640 35. Jayachandran M, Chung SSM, Xu B. A critical review of the relationship between dietary

641 components, the gut microbe Akkermansia muciniphila, and human health. Crit Rev Food Sci Nutr.

642 2020;60(13):2265-2276. doi:10.1080/10408398.2019.1632789

643 36. Anhê FF, Roy D, Pilon G, et al. A polyphenol-rich cranberry extract protects from diet-induced 644 obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp.

- 645 population in the gut microbiota of mice. Gut. 2015;64(6):872-883. doi:10.1136/gutjnl-2014-307142
- 646 Willemsen LEM, Koetsier MA, van Deventer SJH, van Tol E a. F. Short chain fatty acids 37. 647 stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2)
- 648 production by intestinal myofibroblasts. Gut. 2003;52(10):1442-1447. doi:10.1136/gut.52.10.1442
- 649 Crittenden S, Goepp M, Pollock J, et al. Prostaglandin E2 promotes intestinal inflammation via 38.
- 650 inhibiting microbiota-dependent regulatory T cells. Sci Adv. 2021;7(7). doi:10.1126/sciadv.abd7954
- 651 Li O, Zhang O, Wang M, Zhao S, Xu G, Li J. n-3 polyunsaturated fatty acids prevent disruption 39. 652 of epithelial barrier function induced by proinflammatory cytokines. Mol Immunol. 2008;45(5):1356-

653 1365. doi:10.1016/j.molimm.2007.09.003

654 40. Lallès J-P. Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition. Nutr 655

Rev. 2019:77(10):710-724. doi:10.1093/nutrit/nuz015

656 41. Sanguansri L, Shen Z, Weerakkody R, Barnes M, Lockett T, Augustin MA. Omega-3 fatty acids 657 in ileal effluent after consuming different foods containing microencapsulated fish oil powder - an

- 658 ileostomy study. Food Funct. 2013;4(1):74-82. doi:10.1039/c2fo30133d
- 659 42. Zhang Y-G, Xia Y, Lu R, Sun J. Inflammation and intestinal leakiness in older HIV+ individuals
- 660 with fish oil treatment. Genes Dis. 2018;5(3):220-225. doi:10.1016/j.gendis.2018.07.001

Characteristic	Tertile 1 , $N = 28^{T}$	Tertile 2 , $N = 29^{1}$	Tertile 3 , $N = 31^{7}$	p-value ²
ω -3/ ω -6 PUFA ratio tertiles	<0.07	0.07-0.27	>0.27	
Age (years)	54 (48, 59)	53 (49, 57)	56 (48, 62)	0.79
Body Mass Index (kg/m ²)	26.1 (23.1, 29.5)	27.2 (23.4, 32.0)	26.9 (23.2, 28.8)	0.32
Female	21 (75%)	22 (76%)	22 (71%)	0.94
Nonsteroidal anti-inflammatory drug (NSAID) use	5 (18%)	8 (28%)	3 (9.7%)	0.14
Lipopolysaccharide (LPS) binding protein (µg/ml serum)	15 (12, 24)	15 (12, 19)	15 (11, 21)	0.91
Prostaglandin E ₂ (colon, pg/mg protein)	16 (10, 26)	12 (4, 23)	14 (7, 24)	0.38
Shannon Index	2.52 (2.39, 2.63)	2.48 (2.37, 2.55)	2.33 (2.02, 2.52)	0.03
Serum ω -3 PUFA ² (%)	3.16 (2.67, 3.62)	3.38 (2.77, 3.73)	4.33 (3.50, 5.33)	< 0.001
Serum ω -6 PUFA ² (%)	37 (35, 43)	36 (33, 43)	38 (33, 43)	0.62
Serum ω -3/ ω -6 PUFA ratio	0.08 (0.07, 0.10)	0.09 (0.08, 0.10)	0.11 (0.09, 0.14)	< 0.001
Dietary ω-3 PUFA (g/day)	0.75 (0.58, 0.87)	0.74 (0.56, 1.04)	0.79 (0.56, 1.02)	0.88
Dietary ω-6 PUFA (g/day)	6.94 (5.97, 8.14)	6.75 (5.87, 8.38)	6.20 (5.44, 7.47)	0.32
Dietary ω-3/ω-6 PUFA ratio	0.11 (0.09, 0.13)	0.11 (0.10, 0.14)	0.13 (0.10, 0.16)	0.24
Colon tissue Saturated fatty acids ² (%)	32.1 (27.0, 34.8)	32.6 (31.4, 35.3)	32.6 (31.3, 33.1)	0.21
Colon tissue Monounsaturated fatty acids ² (%)	31.4 (28.1, 36.1)	32.2 (28.7, 33.9)	31.6 (29.1, 32.5)	0.91
¹ Summary statistics are presented a chi-square test of independence for			performed were the Kr	uskal-Wallis test or the

Table 1. Baseline characteristics of Healthy Dietary Study participants by tertiles of colonic mucosal ω -3/ ω -6 PUFA (polyunsaturated fatty acids) ratios at baseline

² Fatty acids in serum and colon tissue are shown as percent of total fatty acids analyzed.

Table 2. Changes in dietary, serum and colonic mucosal fatty acid content before and after intervention in the Healthy Eating Study by diet arm assignment.

Fatty acid %	Healthy Eating (n = 42)	Mediterranean (n = 44)	Total (n = 86)	
	Median change ¹ (95 CI%) ²	Median change ¹ (95 CI%) ²	Median change ¹ (95 CI%) ²	
MUFA ³ (%) (tissue)	0.67 (-0.44, 1.63)	0.36 (-1.10, 1.55)	0.50 (-0.34, 1.25)	
$MUFA^{3}$ (%) (serum)	0.40 (-0.86, 1.52)	1.77 (0.60, 3.13)	1.06 (0.21, 1.91)	
ω-6 PUFA ⁴ (%) (tissue)	-0.17 (-1.37, 0.88)	-0.29 (-1.22, 0.98)	-0.23 (-0.97, 0.54)	
ω-3 PUFA ⁴ (%) (tissue)	0.42 (0.07, 0.73)	0.48 (0.17, 0.76)	0.44 (0.22, 0.66)	
ω-3/ω-6 ratio (tissue)	0.01 (0.001, 0.02)	0.01 (0.006, 0.03)	0.01 (0.007, 0.02)	
ω-6 PUFA ⁴ (%) (diet)	-0.20 (-0.91, 0.62)	-1.81 (- 2.50, -1.15)	-1.04 (-0.54, -1.54)	
ω-3 PUFA ⁴ (%) (diet)	0.11 (0.005, 0.24)	0.07 (-0.11, 0.26)	0.08 (-0.007, 0.20)	
ω -3/ ω -6 ratio (diet)	0.02 (0.004, 0.03)	0.05 (0.02, 0.09)	0.03 (0.02, 0.05)	
ω-6 PUFA ⁴ (%, serum)	-0.13 (-1.26, 1.01)	-1.73 (-2.92, -0.41)	-1.04 (-1.73, -0.25)	
ω-3 PUFA ⁴ (%, serum)	0.26 (0.02, 0.67)	0.34 (-0.06, 0.71)	0.32 (0.10, 0.57)	
ω-3/ω-6 ratio (serum)	0.01 (-0.001, 0.02)	0.01 (0.002, 0.02)	0.01 (0.003, 0.02)	

 2 95% confidence intervals calculated with Wilcoxon signed rank test.

³ Monounsaturated fatty acid (MUFA)

⁴ Polyunsaturated fatty acid (PUFA)

Bolded values are significant with P-value<0.05

Table 3. Linear regression modeling of colonic mucosal variables (ω -3/ ω -6 fatty acid ratios, PGE₂ concentration in colon, cyclooxygenase (COX)-1 and 2 gene expression in colon) at 6 months as a factor of log change in *Akkermansia* abundance levels in all 86 individuals after dietary intervention adjusting for baseline colonic mucosal variable values. The data shown is the adjusted β regression coefficient and 95% confidence interval (CI). The adjusted R² represents the fraction of variability in the colonic mucosal variable at 6 months that is explained by the linear regression model¹.

Characteristic	Change in ω -3 PUFA/ ω -6 PUFA ²	Change in PGE2	Change in COX-1	Change in COX-2
	Adjusted R ² =0.56	Adjusted R ² =0.58	Adjusted R ² =0.22	Adjusted R ² =0.22
Overall model				
Tissue n-3 PUFA/ n-6 PUFA (baseline)	0.70 (0.56, 0.84)			
Tissue PGE2 (baseline)		0.81 (0.63, 1.0)		
Tissue COX-1 (baseline)			0.75 (0.54, 1.0)	
Tissue COX-2 (baseline)				0.77 (0.57, 1.0)
Akkermansia (log change)	0.13 (0.02, 0.24)	-37 (-66, -6.8)	1.6 (-3.9, 0.64)	-0.19 (0.73, 0.35)
Dietary n-3 PUFA/ n-6 PUFA (after dietary intervention)	-0.01(-0.10, 0.07)	5.6 (-17, 28)	-1.2 (-2.9, 0.54)	0.32 (-0.19, 0.83)

¹ Multivariate linear regression with colonic mucosal variable at 6 months as the dependent variable adjusting for baseline colonic mucosal variable value, log change in *Akkermansia*, dietary colonic ω -3/ ω -6 PUFA at baseline, age, sex, and BMI. Bolded values are significant in the model with P-value<0.05

² Abbreviations used are: polyunsaturated fatty acids (PUFA), Prostaglandin E2 (PGE2), Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2).




Figure 1. Alpha diversity, accessed by Shannon Index, across tertiles of A) dietary, B) serum and C) colonic mucosal ω -3/ ω -6 PUFA levels after 6 months of dietary intervention.

662 Figure 2. Between microbial community differences across tertiles of A) dietary, B) serum and C) colonic 663 mucosal ω-3/ω-6 PUFA levels following dietary intervention. The circles represent the different tertiles of 664 ω-3/ω-6 PUFA ratios in diet, serum and colon biopsies. Non-metric multidimensional scaling (NMDS).




Figure 3. Correlation between taxon abundance and dietary, serum and colonic mucosal ω -3/ ω -6 PUFA ratios before and after 6 months of dietary intervention.

